Manganese-enhanced T1 mapping in the myocardium of normal and infarcted hearts.

Citation for published version:
Spath, N, Lilburn, D, Gray, G, Le Page, L, Papanastasiou, G, Lennen, RJ, Janiczek, RL, Dweck, M, Newby, D, Yang, P, Jansen, M, Semple, S & Dweck, M 2018, ‘Manganese-enhanced T1 mapping in the myocardium of normal and infarcted hearts.’, Contrast Media and Molecular Imaging. https://doi.org/10.1155/2018/9641527

Digital Object Identifier (DOI):
10.1155/2018/9641527

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Contrast Media and Molecular Imaging

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Manganese-enhanced T₁ mapping in the myocardium of normal and infarcted hearts

Spath NB¹*, David Lilburn²*, Gray GA¹, Le Page LM¹, Papanastasiou G¹, Lennen RJ¹,³, Janiczek , RL⁶ Dweck MR¹,⁴, Newby DE¹,⁴, Yang PC⁵†, Jansen MA¹,³†, Semple SI¹†

1. British Heart Foundation Centre of Cardiovascular Science, University of Edinburgh, UK
2. Centre for Inflammation Research, University of Edinburgh, UK
3. Edinburgh Preclinical Imaging, University of Edinburgh, UK
4. Department of Cardiology, Royal Infirmary of Edinburgh, UK
5. Department of Cardiology, Stanford University, Stanford, CA, US
6. GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, UK

¹ Current address: Peninsula Radiology Academy, Plymouth Hospitals NHS Trust, Plymouth, UK
* The first two authors contributed equally to this work.
† Co-senior authorship

Corresponding Author: Dr Nick Spath, Department of Cardiovascular Sciences, Chancellor’s Building, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4SB, UK
Telephone: +44 (0) 131 242 6427
Email: nick.spath@ed.ac.uk

Running Title: MEMRI of Normal and Infarcted Myocardium
Abstract

Background
Manganese-enhanced MRI (MEMRI) has the potential to identify viable myocardium and quantify calcium influx and handling. Two distinct manganese contrast media have been developed for clinical application, mangafodipir and EVP1001-1, employing different strategies to mitigate against adverse effects resulting from calcium-channel agonism. Mangafodipir delivers manganese ions as a chelate and EVP1001-1 co-administers calcium gluconate. Using myocardial T1 mapping, we aimed to explore chelated and non-chelated manganese contrast agents, their mechanism of myocardial uptake, and their application to infarcted hearts.

Methods
T1 mapping was performed in healthy adult male Sprague-Dawley rats using a 7T MRI scanner before and after non-chelated (EVP1001-1 or MnCl2 [22 μmol/kg]) or chelated (mangafodipir, [22-44 μmol/kg]) manganese-based contrast media in the presence of calcium channel blockade (diltiazem, 100-200 μmol/kg/min) or sodium chloride (0.9%). A second cohort of rats underwent surgery to induce anterior myocardial infarction by permanent coronary artery ligation, or sham surgery. Infarcted rats were imaged with standard gadolinium delayed-enhancement MRI (DEMRI) with inversion recovery techniques (DEMRI inversion recovery) as well as DEMRI T1 mapping. A subsequent MEMRI scan was performed 48 h later using either
non-chelated or chelated manganese and T₁ mapping. Finally, animals were culled at 12 weeks and infarct size was quantified histologically with Masson’s trichrome (MTC).

Results

Both manganese agents induced concentration-dependent shortening of myocardial T₁ values. This was greatest with non-chelated manganese, and could be inhibited by 30-43% with calcium-channel blockade. Manganese imaging successfully delineated the area of myocardial infarction. Indeed, irrespective of the manganese agent there was good agreement between infarct size on MEMRI T₁ mapping and histology (bias 1.4%, 95% CI -14.8 to 17.1 P>0.05). In contrast, DEMRI inversion recovery overestimated infarct size (bias 11.4%, 95% CI -9.1 to 31.8 P=0.002), as did DEMRI T₁ mapping (bias 8.2%, 95% CI -10.7 to 27.2 P=0.008). Increased manganese uptake was also observed in the remote myocardium, with remote myocardial ΔT₁ inversely correlating with left ventricular ejection fraction post myocardial infarction (r = -0.61, P = 0.022).

Conclusions

MEMRI causes concentration and calcium channel-dependent myocardial T₁ shortening. MEMRI with T₁ mapping provides an accurate assessment of infarct size and can also identify changes in calcium handling in the remote myocardium. This technique has potential applications for the assessment of myocardial viability, remodelling and regeneration.

Keywords
Introduction

With major and sustained advances in imaging techniques over the past 3 decades, magnetic resonance imaging (MRI), along with other advanced modalities such as positron emission tomography (PET), has become an essential element to non-invasive structural and functional cardiac imaging [1,2,3]. Current standard clinical methods use inversion recovery delayed enhancement sequences after gadolinium-based contrast administration to image myocardial scar. This allows assessment of viability by assessing the transmural extent of myocardial scar and is used to predict prognosis, guiding the appropriateness of coronary revascularization [4], with excellent reproducibility [5]. Although an invaluable tool in viability assessment, the non-selective passive extracellular redistribution of gadolinium is unable to characterise and define viable myocardium directly [6]. Indeed, quantification by gadolinium delayed enhancement MRI (DEMRI) is subject to overestimation of acute infarct size due to tissue oedema [7]. It is also associated with imaging artefact and interpretation bias in challenging patient populations. Furthermore, whilst significant advances have enabled multiparametric MRI assessment of gadolinium distribution and dynamics to help determine aetiology [8], in practice the different patterns of late enhancement are neither completely specific nor sensitive for different forms
of cardiac pathology where significant overlap is seen, as with aortic stenosis and cardiac sarcoidosis [9,10,11].

There has been increasing interest in a range of alternative contrast media [12] to broaden the capabilities and functional assessments of MRI. Manganese, a paramagnetic calcium analogue, enters active cardiomyocytes via voltage-gated calcium-channels, increasing MRI-detectable $T_1$ relaxivity [13]. As such, manganese-enhanced MRI (MEMRI) has the potential to quantify calcium influx and handling directly, and to identify functional cardiomyocytes actively cycling calcium. Manganese-based contrast media can exist in either chelated (e.g. mangafodipir, manganese dipyridoxyl diphosphate, Mn-DPDP), or non-chelated forms (e.g. EVP1001-1, manganese gluconate with calcium gluconate [14]) and their uptake appears predominantly dependent on the activity of voltage-gated calcium channels during excitation-contraction coupling [15,16,17]. The different formulations of these manganese contrast media reflect different strategies to address adverse effects of manganese resulting from calcium-channel agonism which would otherwise be prohibitive to clinical use. Mangafodipir delivers manganese ions in the form of a chelated agent, similar to conventional MRI contrast agents, resulting in a lower effective circulating dose of manganese ions. Conversely, EVP1001-1 utilises co-administration of calcium, in the form of calcium gluconate, to negate toxicity. Both techniques have established safety and tolerability in clinical studies as well as efficacy in MRI contrast imaging.

Whilst short term cardiac safety of intravenous MnCl$_2$ has been suggested in a pilot study of 15
healthy volunteers at an equivalent molar dose [18], due to the risk of acute toxicity in cardiac
patients, there is no expectation that MnCl₂ be developed further for clinical utility. However,
given that established clinical safety has been demonstrated for both EVP1001-1 and
mangafodipir at doses required for cardiac MRI, there is widespread application for both
mangafodipir and EVP1001-1, notably for cardiac imaging. Preclinical studies with mangafodipir
and MnCl₂ in healthy myocardium and EVP1001-1 in myocardial infarction models have
described myocardial T₁ shortening properties [19] and demonstrated favourable agreement
with histological infarct assessment [20]. Moreover, recent pre-clinical studies have suggested
that MEMRI can lead to better infarct discrimination and the identification of viable
myocardium [21] as well as the ability to assess engraftment of myocardial stem cells [22].

Despite longstanding knowledge of the paramagnetic properties of manganese, the
development and clinical translation of manganese contrast agents has been limited by early
issues with toxicity and the subsequent widespread utility of gadolinium agents which have
since dominated clinical use in the field. More recently, with concerns about neurological
accumulation of some gadolinium agents [23,24,25], and as problems with acute manganese
toxicity have been overcome, there is scope to revisit this agent with high potential in cardiac
imaging.

Given the potential benefits of MEMRI, we aimed to compare myocardial enhancement using
chelated and non-chelated manganese-based contrast media, and to determine the
contribution of calcium-channels to their uptake. This study represents a novel head-to-head
comparison of three manganese contrast agents, using $T_1$ mapping to assess and compare their respective $T_1$ shortening properties, utility and accuracy in quantifying myocardial infarction as compared to DEMRI (inversion recovery and $T_1$ mapping) and histological analysis, and explore altered calcium-handling in remodelling myocardium. This preclinical work is crucial to inform clinical translation and further development of the potential of MEMRI in myocardial viability assessment.

Methods

All studies were approved by the University of Edinburgh Animal Welfare and Ethical Review Body and were carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986. Male Sprague Dawley rats (250-400g, n=55) were purchased from Charles River Ltd (Haddington, UK) and housed, with free access to food and water, in the Central Bioresource Services, University of Edinburgh for 7 days prior to use in the study.

Magnetic Resonance Imaging

All MRI experiments were performed using a 7T horizontal bore NMR spectrometer (Agilent Technologies, Yarnton, UK), equipped with a high-performance gradient insert (120 mm inner diameter), maximum gradient strength 400 mT/m. Rats were anaesthetised with 1.5-2% isoflurane (Zoetis Ltd., London UK) in oxygen/air (50/50, 1 L/min) with subsequent cannulation of the tail vein for drug/contrast agent administration. The animals were secured in a cradle
(Rapid Biomedical GmbH, Rimpar, Germany). The heart rate, respiration rate, and rectal temperature were monitored (Model 1030 monitoring and gating system, Small Animal Instruments Inc. Stony Brook, NY, USA), with body temperature maintained at 37°C by a heat fan. A 72-mm quadrature volume coil was used for transmission with signal reception by a four-channel phased array coil (Rapid Biomedical GmbH, Rimpar, Germany).

Scout images were taken to confirm correct positioning and to orientate 9x2mm axial slices from the aortic valve annulus to the apex, perpendicular to the interventricular septum (short axis slices). The slice plan was carefully replicated between scans by ensuring the same slice plan methodology, which was agreed by two operators at the time of scanning to agree adequate orientation. Selection was then made of the mid-ventricle short axis slice for further interrogation with cine and the T1 mapping sequence. Long-axis cines and a short-axis stack were acquired (to allow left ventricular ejection fraction calculation), with a cardiac-gated gradient echo imaging (TR=1×R-R interval; TE=1.4ms; flip angle=15°; FOV=50×50mm²; matrix=128×128; slice thickness=1.5mm).

T1 mapping for calculation of regional left ventricular myocardial T1 relaxation times was accomplished using a gradient-echo, cardiac-gated Modified Look-Locker Inversion recovery sequence (MoLLI) [26] whereby 14-20 images were acquired at unique inversion times (dependent on heart rate, ranging from approximately 0.20 to 3.00s) with the TRinversion>3×T1 of myocardium (TRinversion>4.50s). Imaging readout was with a cardiac fast gradient echo (TR=3.50ms; TE=1.77ms; flip angle=10°, matrix 128×128; ETL=8; FOV=50×50mm²; in-plane...
resolution=0.39×0.39mm²; trigger delay=1xR-R; slice thickness=2mm; 8 signal averages) to compensate for respiratory motion.

Manganese Enhanced MRI of Healthy Rat Myocardium

EVP1001-1 (SeeMore™, Eagle Vision Pharmaceuticals Corporation, Downingtown, PA, USA) was administered as an intravenous bolus at the manufacturer’s recommended dosage of 22 μmol/kg manganese over 3-4 min. Mangafodipir (Teslascan™, IC Targets AS, Oslo, Norway) was similarly administered as a bolus of 22 or 44 μmol/kg manganese over 3-4 min. Manganese chloride solution (MnCl₂) was prepared using MnCl₂•4H₂O (Sigma-Aldrich Ltd, Gillingham, UK) and sterile water (Sigma-Aldrich Ltd, Gillingham, UK), 22 μmol/kg manganese administered over 3-4 min. All manganese contrast media were delivered in volumes of 2.2 mL/kg, diluted with 0.9% saline solution (Sigma-Aldrich Ltd, Gillingham, UK), to maintain the rate of manganese delivery constant between agents.

Diltiazem (Sigma-Aldrich Ltd, Gillingham, UK) diluted with 0.9% saline solution was infused at 100 μmol/kg/min intravenously, increased to approximately 120-200 μmol/kg/min until a satisfactory chronotropic response was achieved (reduction of >10% in heart rate) or the upper limit was reached. Infusion was commenced approximately 10 min prior to T₁ mapping to ensure stable and adequate heart rate response. Control administrations consisted of a similar volume (8 mL/kg) of 0.9% saline over 180 min. Administration of all agents was followed by a further saline flush of 0.4 mL to ensure complete delivery to the circulation accounting for dead space in the fine bore intravenous line. T₁ mapping was performed in all animals at baseline and
then at approximately 5, 20, 40 and 60 min post-manganese contrast media administration, while cine imaging was performed in a cohort of animals at approximately 15, 30 and 50 min post contrast. The time intervals were determined by technical considerations relating to the length of time required for the $T_1$ mapping sequences.

**Myocardial Infarction Model**

Rats were anaesthetised with isoflurane (5% in 1.5 L/min oxygen for induction), followed by intraperitoneal ketamine 100 mg/kg (Zoetis Ltd, London, UK) and medetomidine 1 mg/kg (Orion Pharma, Espoo, Finland) for maintenance anaesthesia. Buprenorphine 0.05 mg/kg (Alstoe Ltd, York, UK) was administered immediately before and 24 hours post-operatively for analgesia. Tracheal intubation was achieved under direct vision and ventilation was maintained with a rodent ventilator (Harvard Apparatus Model 683, MA, USA, tidal volume 2.5 cm$^3$, respiratory rate 60/min).

Myocardial infarction was induced as we have previously described [27]. Briefly, the skin was incised at the level of the left third and fourth ribs where the pectoral muscles were divided and retracted. Left lateral thoracotomy was then performed. With minimal handling, the pericardium was ruptured and the heart gently exteriorised from the thorax and a non-absorbable 5-0 ligature was placed around the left anterior descending coronary artery just above the bifurcation of the first diagonal, and manoeuvred back into position. Before wound closure, a drain was inserted to assist with removal of air and fluid from the thorax. Once removed, the wound was then closed in three layers. Sham animals underwent identical
surgery with pericardial rupture although the suture placed through the myocardium was not tightened to cause infarction. Animals were recovered with intraperitoneal atipamezole 0.1 mg/kg (Orion Pharma, Espoo, Finland) and extubated once spontaneous ventilation was established, housed at 30°C for 24 hours and given sterile sodium chloride 0.9% 0.01 mL/g fluid therapy subcutaneously. After 24 hours, normal housing conditions were resumed.

**Myocardial Infarction Imaging**

Three weeks post-operatively, rats first underwent DEMRI scanning, under Isoflurane anaesthesia as described above. Scout images were taken to confirm correct positioning and to orientate 9x2 mm axial slices from the aortic valve annulus to the apex, perpendicular to the interventricular septum. Cine images were then acquired in long and short-axis views as outlined above. Standard DEMRI inversion recovery was performed using gadolinium complex (gadobenate dimeglumine, Bracco S.p.A, Milan, Italy) with 0.5 mmol/kg administered intravenously via slow injection into the tail vein over 1-2 min. Standard inversion recovery prepared imaging with myocardial nulling was performed 10 min following injection (inversion recovery gradient echo, TI=2.3x R-R [typical R-R 150-200ms], TR=500 ms; TE=1.6 ms; flip angle=90°; FOV=50x50mm²; matrix=128x128). Due to information gained from the healthy animal data with the manganese contrast agent experiments (see Results section) as well as technical considerations (i.e. pulse sequence duration), DEMRI T₁ mapping was performed at 20 min following contrast injection upon completion of inversion recovery, at the maximal infarct slice as defined by the cine images (MoLLI: TR>4.5 sec; TE=1.7 ms; flip angle=10°; matrix=128x128; ETL=8; FOV=50x50; 20 time points; trigger delay=1xR-R; slice thickness=2mm;
8 signal averages). Animals were allowed to recover following the scan.

MEMRI was performed 48 h after the DEMRI protocol. Scout images were taken followed by a single short axis cine at the maximal infarct slice, using the method outlined above. MEMRI T$_1$ mapping was then achieved using one of two manganese-based MRI contrast media being developed for clinical use; EVP1001-1 (n=8) and mangafodipir (n=9) at doses of 22 and 44 μmol/kg respectively, administered via slow intravenous injection into the tail vein over 1-2 min. T$_1$ mapping was performed at the maximal infarct slice (EVP1001-1, 20 min post injection; mangafodipir 40 min post-injection) defined by the DEMRI scan acquired in the first imaging session. The doses selected of EVP1001-1 and mangafodipir and the timings of the T$_1$ mapping sequences post-manganese contrast agent administration were informed by the healthy animal data to ensure similar degrees of T$_1$ enhancement and therefore sensitivity to detect myocardial viability. Finally, a cine acquisition in the short axis at the maximal infarct slice was repeated following contrast injection. Animals were allowed to recover following the scan.

At 12 weeks post-surgery, DEMRI and MEMRI (48 h apart) were repeated using the identical protocols described above. Animals received the same manganese contrast agent at both time points. MRI parameters were unchanged with the exception of an increased FOV (55x55mm) on account of growth of the animals. After the second MEMRI scan, animals were culled by exsanguination by femoral puncture under anaesthesia for tissue harvest. Figure 1 displays a flow chart summarising the imaging of the myocardial infarction cohort.
Figure 1. Myocardial infarction experimental protocol

Flow-chart detailing timing of surgery and imaging with different contrast agents.

Pathology

Hearts were fixed by immersion in 4% paraformaldehyde for 24 hours before being transferred to 70% ethanol and processed to paraffin wax for sectioning thereafter. Serial 5 µm sections were taken at intervals in the short axis from apex to base, corresponding to MRI short axis T<sub>1</sub> mapping data. Staining was performed with Masson’s trichrome (MTC) to delineate areas of collagenous fibrosis, staining infarct blue and non-infarct purple, before mounting for computer-aided analysis. Slides were scanned at 20x magnification on a Zeiss Axioscan Z1 (Carl Zeiss AG, Oberkochen, Germany) with infarct size calculated as a percentage of total left ventricular area at the comparable maximal infarct slice defined by MRI. Automated tissue detection was conducted using Tissue Studio v2.4 (Definiens AG, Munich, Germany) as follows: A training set of 4 images was automatically segmented and segments within three 50x50µm regions comprising remote myocardium, infarct, and cross-over regions from each training image (12 regions in total) were manually classified as “Normal myocardium”, “Collagen”, and “non-tissue”. These manual classification samples were used to train the software’s automated classification algorithm which was then applied to all images in the dataset. Automated detection produced pixel counts and areas for the ROIs within the left ventricle, from which percentage infarct area at maximal infarct slice was calculated.

Image Analysis
Quantitative analysis of manganese accumulation was achieved by calculation of regional T\textsubscript{1} relaxation times before and after administration of manganese contrast media. The 14-20 images at unique inversion times were exported offline and combined to generate T\textsubscript{1} maps using commercially available software (CVI\textsuperscript{4.2\textregistered}, Circle Cardiovascular Imaging, Calgary, Canada) using three-parameter non-linear curve fitting as previously described [26].

During the lengthy \textit{in vivo} experiments it was noted that there was an approximate ±10% variation in the measurement of T\textsubscript{1} values in healthy myocardium and skeletal muscle before the administration of manganese contrast agents. In an attempt to compensate for these fluctuations in T\textsubscript{1} measurements myocardial T\textsubscript{1} values were normalized to the T\textsubscript{1} of skeletal muscle, where it was noted that the T\textsubscript{1} values did not vary over the time course of the contrast agent infusion (as detailed in section S1 of the supplemental material). Final normalized T\textsubscript{1} maps were then generated in Matlab (MathWorks Inc., USA) with normalized myocardial T\textsubscript{1} values obtained from regions of interest (ROIs) drawn on the left ventricle. Change in T\textsubscript{1} between the baseline myocardial T\textsubscript{1} and the myocardial T\textsubscript{1} at each time point was then calculated (ΔT\textsubscript{1}). Infarct was defined as 2 × standard deviations of infarcted and remote myocardial T\textsubscript{1} with an averaged intermediate value representing borderzone myocardium.

**Statistical Analysis**

Data are presented as mean ± standard deviation unless otherwise stated. Comparison of the time course curves between the saline (control) and diltiazem-infused groups for each of the 22 μmol/kg MnCl\textsubscript{2}, 22 μmol/kg EVP1001-1, and 44 μmol/kg mangafodipir was performed using a
two-way analysis of variance (ANOVA) with post-hoc multiple comparison Bonferroni tests for individual time points (compared to baseline). For infarct quantification, DEMRI inversion recovery, DEMRI $T_1$ mapping, MEMRI $T_1$ mapping and MTC assessments were compared using Wilcoxon signed rank test (2-tailed), with post-hoc multiple comparison Bonferroni testing. Bland-Altman plots were used to assess agreement between DEMRI inversion recovery, DEMRI $T_1$ mapping, MEMRI $T_1$ mapping and MTC, and Spearman correlation tested for relationship between changes in remote $T_1$ between early and late time points ($\Delta T_1$, dependent variable) and ejection fraction (independent variable). Statistical analysis was performed using GraphPad PRISM (v.7.0, GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was taken as two-sided $P<0.05$. 
Results

Comparative and Calcium Channel Dependency of MEMRI Contrast Media

Thirty-one animals underwent experiments with the manganese contrast agent with a concurrent infusion of either 0.9% saline or diltiazem at a median age of 84±19 days, with a median weight of 356±45 g. Four animals (two control and two with diltiazem) were excluded as venous access was compromised resulting in unpredictable contrast agent administration. MnCl$_2$, EVP1001-1 and mangafodipir altered $T_1$ relaxivity values evident with $T_1$ mapping (Figure 2A). Mean shortening of myocardial $T_1$ values was greater with EVP1001-1 as compared to similar concentrations of mangafodipir but commensurate to those observed with MnCl$_2$ (Figure 2B). Peak changes in $T_1$ values were obtained by 20 min with EVP1001-1 and MnCl$_2$, with persistent $T_1$ shortening at 60 min. The magnitude of $T_1$ shortening was dose-dependent for mangafodipir with little change between 40 and 60 min time points (Figure 2B). Overall $T_1$ shortening with MnCl$_2$, EVP1001-1 and mangafodipir (all 22 µmol/kg) at 20 min were 29.4±5.1%, 28.0±4.4% and 8.5±4.2% respectively. To improve the degree of $T_1$ shortening with mangafodipir the dosage of manganese administered was increased to 44 µmol/kg resulting in a $T_1$ shortening of 12.8±3.4% at 20 min which increased to 15.0±2.9% at 40 min. MnCl$_2$ and EVP1001-1 values at 40 min post-administration were unchanged.

Figure 2. $T_1$ shortening of manganese contrast media over time.

A. Normalized $T_1$ maps acquired subsequent to infusion of MnCl$_2$, EVP1001-1 and mangafodipir at 20 minute
intervals up to 60 minutes, with associated gradient echo cine images in end-diastole and end-systole. MnCl₂ (22 μmol/kg), EVP1001-1 (22 μmol/kg) or mangafodipir (44 μmol/kg) was administered intravenously to isoflurane-anaesthetised healthy rats over 3-4 minutes. Rats were simultaneously administered an infusion of 8 mL/kg 0.9% saline over 3-4 minutes. Note the superior degree of T₁ shortening with MnCl₂ and EVP1001-1 at half the molar dosage of manganese as compared to mangafodipir (T₁ reduction of 421.3ms and 357.9ms from baseline with MnCl₂ and EVP1001-1 compared to 222.7ms with mangafodipir). B. Reduction in mean left ventricular T₁ values over 60 minutes with EVP1001-1 and mangafodipir. MnCl₂ (22 μmol/kg; blue), EVP1001-1 (22 μmol/kg; red), mangafodipir (22 [green] or 44 [purple] μmol/kg) was administered to rats (n=4 per group) over 3-4 min. Error bars represent standard deviations from time-points where measurements were recorded (n=4 at each time point). Two-way ANOVA confirmed a dependence of mean myocardial T₁ shortening between each of the contrast agents (p<0.0001).

Pre-treatment with a calcium-channel antagonist (diltiazem) inhibited MEMRI induced T₁ shortening (Table 1). This inhibition was similar between all agents with MnCl₂ experiencing a maximal mean reduction of 30% in T₁ shortening between the 5 and 60 min time points, while EVP1001-1 and mangafodipir experienced reductions of up to 43% and 32% respectively. There were significant differences between the degree of myocardial T₁ shortening due to each manganese contrast agent in the presence of diltiazem as measured by two-way ANOVA (MnCl₂ P=0.0004, EVP1001-1 P<0.0001 and mangafodipir P=0.044).

| Time Point (minutes) | Baseline T₁ (ms) | Mean T₁ shortening (ms) |
|----------------------|------------------|-------------------------|
| MnCl₂ + Saline       | 1286±42          | 366±72  382±72  389±67  351±35      |
Table 1. Effect of diltiazem on manganese-induced T<sub>1</sub> shortening. Healthy rats (group sizes n=4 unless otherwise stated) administered MnCl<sub>2</sub> (22 μmol/kg), EVP1001-1 (22 μmol/kg) or mangafodipir (44 μmol/kg) over 3-4 min with simultaneous administration of 0.9% saline or diltiazem (100-200 μmol/kg/min) infusion.

Note the approximate 30% reduction in mean myocardial T<sub>1</sub> values at each time point, but that there is greater discrimination between the diltiazem and saline infused rats due to the superior T<sub>1</sub> shortening with EVP1001-1. Post-hoc Bonferroni multiple comparisons (manganese agent + saline, manganese agent + diltiazem), significance p<0.05 at each time point as compared to saline control indicated by *

| Group                          | T<sub>1</sub> (ms) | T<sub>1</sub> (ms) | T<sub>1</sub> (ms) | T<sub>1</sub> (ms) |
|-------------------------------|-------------------|-------------------|-------------------|-------------------|
| MnCl<sub>2</sub> + Diltiazem (n=3) | 1180±93           | 290±52            | 288±71            | 276±56            | 274±63            |
| EVP1001-1 + Saline            | 1265±94           | 354±91            | 397±73            | 352±54            | 383±87            |
| EVP1001-1 + Diltiazem         | 1375±38           | 209±27*           | 225±57*           | 211±49            | 226±40*           |
| Mangafodipir + Saline         | 1366±94           | 142±52            | 178±59            | 206±53            | 220±61            |
| Mangafodipir + Diltiazem      | 1219±69           | 96±34             | 128±42            | 158±66            | 177±24            |

Left Ventricular Function

All contrast agents were well-tolerated across all animal groups. Following administration of gadolinium and EVP1001-1, a transient increase in respiratory rate was observed which was self-limiting and resolved within 1 minute. This was seen in healthy animals, shams and infarcted animals. The present study was not designed to assess safety and tolerability and no further adverse effects were observed.

Healthy myocardial left ventricular ejection fraction was measured before and after manganese contrast agent administration to assess for discernible myocardial depression. The mean LVEF
(± standard deviation) and the mean difference in LVEF at each time point from the cohorts of healthy rats administered with each of the manganese contrast agents with concurrent diltiazem (or 0.9% saline control) infusion are shown in Table 2.

| Time point (minutes)        | Baseline | 15       | 30       | 50       |
|----------------------------|----------|----------|----------|----------|
| MnCl₂ + Saline             | 67.5±5.6 | 73.4±6.3 | 72.4±5.6 | 71.1±2.0 |
| Mean Difference (vs. Baseline) | -        | 5.8±1.3* | 4.9±2.6  | 3.6±5.1* |
| MnCl₂ + Diltiazem          | 65.0±8.0 | 58.2±3.9 | 58.3±6.8 | 60.1±12.5|
| Mean Difference (vs. Baseline) | -        | -3.2±0.6*| -3.1±2.6*| -4.8±5.1*|
| EVP1001-1 + Saline         | 65.3±0.7 | 71.0±5.5 | 67.1±2.5 | 67.1±3.8 |
| Mean Difference (vs. Baseline) | -        | 4.0±6.8  | -0.3±2.6 | 0.7±5.5  |
| EVP1001-1 + Diltiazem      | 69.6±6.4 | 68.3±8.4 | 63.4±7.3 | 65.6±7.8 |
| Mean Difference (vs. Baseline) | -        | -0.5±3.7 | -4.1±4.0 | -4.1±3.7 |
| Mangafodipir 22 µmol/kg     | 63.2±6.3 | 66.9 (n=2)| 65.8±8.2| 67.1±7.4 |
| Mean Difference (vs. Baseline) | -        | 6.9 (n=2)| 4.7±7.1 | 2.5±4.5  |
| Mangafodipir 44 µmol/kg + Saline | 73.5±3.1| 76.8 (n=2)| 76.1±4.9| 77.0±4.1 |
| Mean Difference (vs. Baseline) | -        | 3.9 (n=2)| 4.5±1.1 | 4.6±3.6  |
| Mangafodipir 44 µmol/kg + Diltiazem | 64.1±4.8| 64.0±8.1 | 62.5±7.3| 62.0±9.5 |
| Mean Difference (vs. Baseline) | -        | 0.81±6.53| -0.2±6.9| -1.0±4.7 |

Table 2. Mean LVEF and mean difference in LVEF vs. baseline for the cohort of healthy rats administered
**MnCl₂, EVP1001-1 and mangafodipir.** Group sizes n=3 for EVP1001-1 and mangafodipir 22 μmol/kg and n=4 for MnCl₂ and mangafodipir 44 μmol/kg. Calculation of mean only from those time points with n=2 measurements available. Post-hoc Bonferroni multiple comparisons significance P<0.05 at each time point as compared to saline control indicated by *.

No difference was noted between the mean difference in LVEF between baseline and the time points between mangafodipir 22 μmol/kg and mangafodipir 44 μmol/kg (P=0.78) by two-way ANOVA indicating that the higher mangafodipir dosage was well tolerated. There were significant differences detected between the mean difference in LVEF with each of the contrast agents in the presence of diltiazem: MnCl₂ 22 μmol/kg (p<0.001 and significant [p<0.05] at the 15 min and 50 min time points on multiple comparison); EVP1001-1 (p=0.02) and mangafodipir 44 μmol/kg (p=0.04). This may potentially indicate that in the presence of depressed LVEF the manganese contrast agents at the dosages used may further compromise myocardial contractility, however further study would be required beyond this pre-clinical study with low numbers of animals. There was no change in left ventricular ejection fraction following manganese administration with any of the agents in the saline control animals. This data supports the assertion that there is minimal change in left ventricular myocardial function in healthy animals with the dosages used in this study. In the infarct group, left ventricular function was assessed at the maximal infarct slice by fractional area change (single slice only due to concern over prolonged anaesthetic risk) before and after manganese-based contrast media administration to assess for discernible myocardial depression. There was no change in fractional area change at this slice following administration of either EVP1001-1 or mangafodipir at early (0.1±1.5%, P=0.82 and 0.1±2.2%, P=0.88) or late (0.2±1.2%, P=0.74 and
0.3±1.8%, P=0.70) imaging time points respectively.

Effect of $T_1$ Relaxivity of Contrast Media

On comparison of the effect of different contrast agents on $T_1$ relaxivity, the difference in mean $T_1$ between infarcted and remote myocardium was highly significant across all contrast agents as well as native $T_1$ mapping. Remote myocardial mean $T_1$ was similar between both mangafodipir and EVP1001-1 (Figure 3).

Figure 3. Comparison of the effects of contrast agents on $T_1$ relaxivity.

Mean $T_1$ is significantly different between remote and infarcted areas of myocardium for all agents and native $T_1$ mapping (all P<0.0001). Remote myocardial $T_1$ between manganese contrast agents was comparable (P=0.064).

Viability Assessment Post-myocardial Infarction

Eighteen animals underwent successful surgery (14 permanent coronary artery ligation surgery, 4 sham surgery) at a median age of 58±7 days, with a median weight of 262±52 g. One animal in the surgical cohort died unexpectedly 11 days after surgery, resulting in 17 animals completing the experimental imaging protocol. A further animal died unexpectedly 31 days after surgery, with large myocardial infarction a likely substrate for ventricular arrhythmia as previously observed [28], and 2 animals failed to recover from MRI at the late time point.

Three weeks following surgery, all animals in the infarct cohort had left ventricular impairment
with anterior wall akinesia and wall thinning associated with a reduced left ventricular ejection fraction (42.2±8.1 versus 68.9±9.4% in sham animals, P<0.001). Myocardial infarction was also associated with higher left ventricular end diastolic volume (1.0±0.2 versus 0.7±0.1 mL, P=0.02) and mass (0.7±0.1 versus 0.6±0.04 g, P=0.03). There were no differences in left ventricular function nor volume between animals administered mangafodipir or EVP1001-1 (left ventricular ejection fraction, 41.49±9.86 and 43.10±6.44% respectively, P=0.76; left ventricular end diastolic volume, 1.02±0.21 versus 0.83±0.07 mL respectively, P=0.18).

Figure 4. Comparison of DEMRI and MEMRI infarct quantification by T₁ mapping.

Mean infarct size as a percentage of left ventricular myocardium at maximal infarct short-axis slice in rats with DEMRI and MEMRI T₁ mapping at two time points; early post-MI (3 weeks, n=13, left panel) and late post-MI (12 weeks, n=12, right panel). Infarct size as assessed by MEMRI T₁ mapping is significantly lower than DEMRI T₁ mapping at 3 weeks (P<0.05), a result which is attenuated at 12 weeks (P=0.067). Error bars represent standard deviation. Example T₁ maps with delayed-enhancement and gradient echo cine images are shown for one animal.

At 12 weeks, DEMRI inversion recovery, DEMRI T₁ mapping and MEMRI T₁ mapping of infarct size all correlated independently with histologically quantified infarct size by MTC (all P<0.05). However, unlike manganese, gadolinium-based assessments tended to over-estimate infarct size.
size by around 10% (DEMRI inversion recovery, bias 11.36%, 95% confidence intervals -9.11 to
31.82, P=0.002; DEMRI $T_1$ mapping, bias 8.25 %, 95% confidence intervals -10.7 to 27.2,
P=0.008; MEMRI $T_1$ mapping, bias 1.14 %, 95% confidence intervals -14.8 to 17.1, P=0.735; with
post-hoc Bonferroni multiple comparisons for P<0.05, Figure 5 A and B).

Figure 5. DEMRI vs MEMRI vs MTC

A. Comparison of magnetic resonance imaging and histological quantification of infarct size. Infarct size as a
percentage of left ventricular myocardium at maximal infarct short-axis slice by DEMRI and MEMRI $T_1$ mapping and
histologically with MTC. Note the inverted $T_1$ colour map configuration between DEMRI $T_1$ mapping and MEMRI $T_1$
mapping, calibrated to define infarct (pink) and remote (green) myocardium with intermediate values (yellow). B.
Bland-Altman plots showing differences between DEMRI inversion recovery (i), DEMRI $T_1$ mapping (ii) and MEMRI
$T_1$ mapping (iii) for each rat heart. The average difference (bias) between the measurements is shown (dashed
lines) ±2xSD (dotted lines) for all three modalities.

There was an inverse correlation between ejection fraction and remote myocardial $\Delta T_1$ ($r=-0.61,$
P=0.022; Figure 6) with greater reduction in remote myocardial $T_1$ at 3 months with increasing
severity of left ventricular impairment. Myocardium remote from the site of infarction (mean $T_1$
of non-infarcted myocardium) appeared to have lower mean MEMRI $T_1$ mapping values at late
(12 week) compared to early (3 week) time points in animals with the largest infarcts by
ejection fraction but this was not statistically significant (mean $\Delta T_1$ -8.39±0.66%, P=0.4, n=3;
sham animals with preserved left ventricular ejection fraction mean $\Delta T_1$ 7.19±5.93%, P=0.7,
n=3).

Figure 6. $\Delta T_1$ in remote myocardium over time vs ejection fraction
Correlation of change in remote myocardial T$_1$ relaxivity between early and late time points with ejection fraction at 12 weeks post-surgery. There is a significant correlation between ejection fraction and T$_1$ reduction between early (3 week) and late (12 week) time points ($r = 0.61$, $P = 0.022$). Standard error of the mean shown as dashed black line.

Discussion

The present study applies myocardial T$_1$ mapping to manganese-enhanced MRI, in healthy myocardium in addition to remote myocardium post-infarction. This novel combination of imaging techniques has been employed to directly compare two distinct manganese contrast agents with conventional DEMRI in the assessment of viability by infarct size, as well as examine altered calcium handling in remodelling myocardium over time, building on previous pilot data in myocardial infarction. This work was designed as a precursor to clinical translation of intra-myocardial contrast imaging, for development of this promising field within cardiac MRI which has potential to improve accuracy of myocardial viability assessment, improve understanding of pathophysiology and monitor response to therapy in different forms of cardiomyopathy.

We have demonstrated that MEMRI causes an ionic, concentration and calcium-channel dependent shortening of myocardial T$_1$ values. We have further shown that MEMRI T$_1$ mapping provides a better estimate of infarct size than DEMRI using both inversion recovery and T$_1$ mapping, and correlates with left ventricular remodelling within the remote myocardium.
following myocardial infarction. We conclude that MEMRI holds major potential for the assessment of myocardial viability, dysfunction and regeneration with wide ranging clinical applicability.

Chelation, concentration and calcium-channel dependence

Biotransformation of MnDPDP occurs by dephosphorylation and simultaneous transmetallation with zinc facilitating MRI-detectable intracellular manganese uptake, as demonstrated in vitro where transmetallation with zinc occurs rapidly, almost to completion, within 1 minute of incubation in human serum [29]. These findings have been reinforced in subsequent animal [30,31] and human studies [32,33]. In the present study, chelated (mangafodipir) and non-chelated (MnCl$_2$ and EVP1001-1) manganese contrast media were compared in healthy myocardium. Intracellular T$_1$ shortening properties of manganese were clearly demonstrated with a reduction in myocardial T$_1$ values of 29.4±5.1%, 28.0±4.4% and 12.8±3.4%, compared to baseline values, with 22 μmol/kg MnCl$_2$ and EVP1001-1 at 20 min, and 44 μmol/kg mangafodipir at 40 min respectively. The paramagnetic performance of manganese when administered as EVP1001-1 was highly comparable to that of MnCl$_2$, with rapid increase in T$_1$ relaxivity over time achieving close to maximal relaxivity by 5 min (Figure 2A). This correlation is expected given intravenous administration of non-chelated manganese ions in both cases. This effect on T$_1$ shortening was sustained at 60 min and an optimal imaging time point of 20 min was adopted to allow for variation in administration dynamics and utilised in the infarcted myocardium MEMRI experiments. A less marked increase in relaxivity was observed with mangafodipir. This is likely to be due to the need for manganese to become unchelated from
the DPDP ligand as above. To achieve reduction in $T_1$ comparable to the non-chelated preparations, the dose of mangafodipir was doubled to 44 $\mu$mol/kg to obtain similar reductions in myocardial $T_1$ (Figure 2B). $T_1$ relaxivity continued to increase over the measured time period although appeared to begin to plateau from 40 min post-administration. An imaging time point of 40 min was selected as a compromise between practicability and allowing adequate time for unchelation of manganese to achieve sufficient intracellular uptake and therefore provide adequate $T_1$ shortening. Inhibition of intracellular manganese uptake was evident from a consistently reduced $T_1$ shortening observed with MnCl$_2$, EVP1001-1 and mangafodipir when co-administered with diltiazem (Table 1). A benzothiazepine, diltiazem binds to L-type calcium-channels at cardiac myocytes and decreases myocardial contractility [13]. Co-administration with manganese-based contrast agents serves to assess manganese uptake in myocardium during calcium channel inhibition. Myocardium in animals pre-treated with diltiazem showed reduction in mean shortening of myocardial $T_1$ values with both clinical-grade agents, but the magnitude of inhibition was greater with EVP1001-1 compared to similar concentrations of mangafodipir. Due to the superior $T_1$ shortening with EVP1001-1 at lower doses, there are potentially greater differences between the diltiazem and saline infused animals. These data reinforce the understanding that intracellular manganese uptake is dependent on both L-type voltage-gated calcium-channel as well as sodium/calcium exchanger activity, as previously demonstrated [34].

MEMRI in myocardial infarction

In myocardial infarction, both DEMRI inversion recovery and $T_1$ mapping consistently
overestimated infarct area 3 weeks post-surgery in comparison to MEMRI T₁ mapping. Both
DEMRI and MEMRI modalities correlated with histopathological infarct quantification by MTC.
However, infarct quantification was similar for histopathology and MEMRI T₁ mapping, whereas
DEMRI consistently overestimated infarct size. Contrast imaging of acute myocardial infarction
with DEMRI inversion recovery is well-established to overestimate infarct size due to
pathologically expanded extracellular space and myocardial oedema. This finding has been
observed with preclinical data from swine ischaemia-reperfusion injury indicating discrepancy
between DEMRI inversion recovery (both in vivo and ex vivo) and histological infarct size at 6 h,
resolving at 7 days [35]. In clinical studies, imaging too early after infarction results in
enhancement of salvaged as well as infarcted myocardium [7] and some degree of myocardial
oedema remains and is stable for 7 days following myocardial infarction, reducing at 14 days
and near-normalising at 6 months [36]. MEMRI mechanistically circumvents the uncertainty of
myocardial oedema as it acts as a specific intracellular agent tracking cardiomyocytes with
functional calcium-handling. Furthermore, permanent arterial occlusion models, as used in the
present surgical protocol, result in substantially less myocardial interstitial oedema than
ischaemia-reperfusion models, even at 24 h [37]. In the present study, gross myocardial
oedema is therefore unlikely to persist at 3 weeks, implicating other factors to account for
overestimation of infarct size by DEMRI techniques. We hypothesise that dual enhancement
with both gadolinium and manganese may occur in areas of injured myocardium where there is
residual calcium transport functionality. Early clinical work has explored MEMRI T₁ mapping as a
technique to define viability in this way using mangafodipir, demonstrating manganese
enhancement in myocardium remote to the infarcted region, 3-4 weeks post-infarction [38].
Whilst MnCl$_2$ carried significant risk of adverse events in cardiac patients which prohibits further clinical development, mangafodipir and EVP1001-1, both having established clinical safety and tolerability, are now primed for clinical applications in cardiac imaging. The clinical significance of viable myocardium defined in this way is as yet unknown and underscores the need for robust clinical trials in this field.

**Detection of altered calcium-handling with MEMRI**

$T_1$ mapping of remote myocardium was compared over time following myocardial infarction allowing time for left ventricular remodelling. Changes in $T_1$ values between early and late time points were compared for each animal. Despite variability between animals, an inverse correlation was observed between ejection fraction and change in $T_1$ value for all animals, including shams. The significance and precise mechanisms underlying this preliminary finding are unconfirmed as there are contradictory data on activity of voltage-gated L-type calcium-channels in heart failure. L-type calcium-channels in remodelling remote myocardium may have a greater propensity to remain open for longer, on account of prolongation of the plateau phase of the cardiac action potential, as compared to uninjured myocardium resulting in greater relative manganese uptake [39]. A study analysing cardiomyocytes from failing human myocardium observed enhancement of single L-type calcium-channel activity compared to non-failing control myocardium, demonstrating both increased availability and open probability [40]. The data from the present study indicate potential for MEMRI to characterise disordered calcium-handling in failing myocardium, but this requires further exploration in clinical translational studies.
Challenges of the preclinical model

The present study has been designed as a proof-of-concept study of MEMRI in ischaemic cardiomyopathy to inform clinical translation of this imaging modality in ischaemic heart disease as well as other forms of cardiomyopathy. The aim was to assess the application of manganese in non-infarcted myocardium undergoing remodelling following infarction rather than specific dynamics of the infarct region acutely after infarction. Therefore, a permanent coronary artery ligation model was used over an ischaemia-reperfusion model. There are several aspects that are specific to preclinical MR imaging of rodents which do not apply to clinical imaging which are relevant. Despite the excellent spatial resolution of the $T_1$ mapping sequence used in this study, the small myocardial volume in conjunction with heart rates in excess of 350 beats per minute, obligate free-breathing acquisition with respiratory rates in excess of 40 breaths per minute (with a high degree of variability in both these parameters) provide significant challenges resulting in prolonged $T_1$ mapping sequences (11-13 minutes) and the margin for error is consequently much narrower than in a clinical equivalent. This constraint resulted in the practical requirement to select one slice representative of the myocardial infarction, rather than acquire a full $T_1$ map short-axis stack. The potential for sampling error between scans was minimized by careful adjudication by two experienced operators at the time of scanning to agree adequate orientation and replicate slice planning methodology, as described above. Whilst unable to guarantee maximal infarct slice, this ensures equivalent slice comparison between scans.
The use of $T_1$ mapping removes the issue of timing in correct nulling, which is made problematic due to the animal-specific issues above. In the imaging of an infarct, it is possible to select an inversion time following manganese administration whereby the infarct is nulled and the myocardium enhances, in an opposite fashion to DEMRI with gadolinium. Inversion recovery imaging with these nulling techniques is easily degraded by artefact of irregular heart rate or breathing and accurate conclusions are highly dependent on the quality of the nulling. Moreover, where more diffuse myocardial processes are concerned, such as remote remodelling in ischaemic cardiomyopathy, $T_1$ mapping offers the ability to quantify the graduation of $T_1$ across all regions of myocardium. Finally, in clinical MR imaging, a motion correction algorithm is applied to the $T_1$ mapping sequence. This algorithm is not available to us in the preclinical setting. These technical factors, unique to the preclinical nature of this study, necessitated the use of normalization of $T_1$ values and underscore the need for clinical translation.

Clinical perspectives

What future diagnostic and therapeutic possibilities does manganese-enhanced cardiac MRI offer the clinician? The prospect of intracellular myocardial tissue characterisation is novel and has far reaching potential. The present study demonstrates unique description of myocardial infarction and viability through calcium-handling which has exciting applications in development of novel therapies in myocardial infarction, recently explored in preclinical ischaemia-reperfusion assessing myocardial regeneration with stem-cell therapy [21] and clinical work establishing safety and tolerability of chelated manganese contrast agents in
ischaemic heart disease[38]. Beyond myocardial infarction, we have demonstrated potential to
detect altered calcium-handling non-invasively and scope for earlier detection and
quantification of cardiomyopathy. The present preclinical study highlights the need for clinical
translation of these agents, where image acquisition is vastly superior, in a patient population
which accurately represents the substrate for disease underlying the pathology.

Conclusion

The present study demonstrates the utility of MEMRI with two distinct agents, chelated and
non-chelated manganese, as a non-invasive imaging modality which can accurately quantify
viable myocardium. Furthermore, these data indicate an ability to detect and quantify altered
calcium-handling in the remodelling remote myocardium. This novel technique has potential to
actively quantify viable myocardium, rather than inferring viability using infarct extent as a
surrogate. Furthermore, calcium handling dysfunction observed in a wide range of
cardiomyopathies and heart failure syndromes eludes current non-invasive investigation; an
application where MEMRI holds great promise. Clinical translation of the work presented here
is an essential next step.

Abbreviations
32

DEMRI: delayed-enhancement magnetic resonance imaging

DPDP: dipyridoxyl diphosphate

ETL: echo train length

FOV: field of view

MEMRI: manganese-enhanced magnetic resonance imaging

MoLLI: modified Look-Locker inversion recovery

MRI: magnetic resonance imaging

MTC: Masson’s trichrome

NMR: nuclear magnetic resonance

ROI: region of interest

TE: echo time

TR: repetition time

Declarations

Ethics approval

Ethical approval was granted for all animal studies by the University of Edinburgh Animal Welfare and Ethical Review Body.

Consent for publication
Not applicable.

Availability of data and material

The datasets generated and/or analysed during the current study are not publicly available due to commercial regulations pertaining to involved third parties, but may be available from the corresponding author on reasonable request.

Competing interests

RLJ is currently employed by GlaxoSmithKline, which contributed to funding for the study through a fellowship awarded to DML. Neither the funding agency nor any outside organization has participated in study design or have any competing interests. GlaxoSmithKline approved the final manuscript.

Funding

DML was supported by a GlaxoSmithKline sponsored research fellowship. NBS is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/17/19/32641). DEN is supported by the British Heart Foundation (CH/09/002, RG/16/10/32375, RM/13/2/30158, RE/13/3/30183) and is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA). The work was funded by the British Heart Foundation through support awarded to NBS and DEN.

Authors’ contributions
NBS and DML acquired, analysed and interpreted the data and compiled the original manuscript. NBS and LLP performed the surgical protocol and contributed to critical revision of the manuscript. MAJ, RJL, DML and NBS undertook imaging protocols and contributed to critical revision of the manuscript. DML, NBS, SIS, MAJ, DEN, GAG, MRD and PCY were involved in study design, supervised the protocols and contributed to critical revision of the manuscript. NBS and GP undertook inter-operator variability studies and analysis. SIS, MAJ and PCY were joint senior supervisors on the project. RLJ supervised DML through the GlaxoSmithKline fellowship, contributed scientifically to this work, and contributed to the critical revision of the manuscript. PCY provided EVP1001-1 and imaging expertise.

Acknowledgements

We thank Phil Yang and Willy Eidsaunet and their respective organisations for provision of contrast media (EVP1001-1 and mangafodipir respectively) as well as their support and expertise throughout this work. Grateful acknowledgements are also made to Dr Daniel Soong for assistance with tissue detection software packages and Melanie McMillan for tissue sample processing.
References

1. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. J Cardiovasc Magn Reson. 2017;19(1), 18.

2. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002 Jul;90(1):29-34.

3. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004 Feb;147(2):218-23.

4. Kohl P, & Windecker S, et al. for the The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2014;35(46), 2541–2619.

5. Thiele H, Kappl MJE, Conradi S, Niebauer J, Hambrecht R, & Schuler G. Reproducibility of Chronic and Acute Infarct Size Measurement by Delayed Enhancement-Magnetic Resonance Imaging. Journal of the American College of Cardiology. 2007;47(8), 1641–1645.

6. Arai AE. The cardiac magnetic resonance (CMR) approach to assessing myocardial viability. Journal of Nuclear Cardiology. 2011;18(6), 1095–1102.

7. Hammer-Hansen S, Bandettini WP, Hsu LY, Leung SW, Shanabag S, Mancini C, et al. Mechanisms for overestimating acute myocardial infarct size with gadolinium-enhanced cardiovascular magnetic resonance imaging in humans: a quantitative and kinetic study. Eur Heart J Cardiovasc Imaging. 2016;17(1):76-84.

8. West AM, & Kramer CM. Cardiovascular Magnetic Resonance Imaging of Myocardial Infarction, Viability, and Cardiomyopathies. Curr Probl Cardiol. 2010;35(4), 176–220.

9. Bax JJ, Delgado V. Advanced imaging in valvular heart disease. Nature Reviews. Cardiology. 2017;14(4), 209–223.

10. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K & Tung R. Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment. Semin Respir Crit Care Med. 2014;35(3):372-390.

11. Franco A, Javidi S, Ruehm SG. Delayed Myocardial Enhancement in Cardiac Magnetic Resonance Imaging. J Radiol Case Rep. 2015;9(6):6-18.

12. Stirrat CG, Alam S, MacGillivray TJ, Gray CD, Dweck MR, Mirsadraee S, et al. Ultrasmall superparamagnetic particles of iron oxide-enhanced magnetic resonance imaging in the assessment of cellular inflammation after myocardial infarction. J Cardiovasc Magn Reson. 2015;17 Suppl 1: 252.

13. Wendland MF. Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to imaging of the heart. NMR in Biomed. 2004;17(8):581–594

14. Harnish, PP, Seoane P, Vessey A. Manganese compositions and methods for MRI. 1999. U.S patent 598083, USA1999 09/11/1999

15. Koretsky AP, & Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed. 2004;17(8):527–531.

16. Bremerich J, Saeed M, Arheden H, Higgins CB, & Wendland MF. Normal and Infarcted Myocardium: Differentiation with Cellular Uptake of Manganese at MR Imaging in a Rat Model. Radiology. 2000;216(2): 524–530.

17. Waghorn B, Edwards T, Yang Y, Chuang KH, Yanasak N, & Hu TCC. Monitoring dynamic alterations in calcium homeostasis by T1-weighted and T1-mapping cardiac manganese-enhanced MRI in a murine myocardial infarction model. NMR in Biomedicine. 2008;21(10):1102–1111.

18. Fernandes JL, Storey P, da Silva JA, de Figueiredo GS, Kalaf JM & Coelho OR. Preliminary assessment of cardiac short term safety and efficacy of manganese chloride for cardiovascular magnetic resonance in humans. J Cardiovasc Magn Reson. 2011;13(1):6.

19. Eriksson R, Johansson L, Bjerner T, Briley Saeko B, Ahlstrom H: Uptake of MnCl2 and mangafodipir trisodium in the myocardium: a magnetic resonance imaging study in pigs. J Magn Reson Imaging. 2004;19:564-569.

20. Storey P, Chen Q, Li W, Seoane PR, Harnish PP, Fogelson L, Harris KR, Prasad PV: Magnetic resonance imaging of myocardial infarction using a manganese-based contrast agent (EVP 1001-1): Preliminary results in a Dog model. J Magn Reson Imaging. 2006;23:228-234.
21. Dash R, Chung J, Ikeno F, Hahn-Windgassen A, Matsuura Y, Bennett MV, et al. Dual Manganese-Enhanced and Delayed Gadolinium-Enhanced MRI Detects Myocardial Border Zone Injury in a Pig Ischemia-Reperfusion Model. Circ Cardiovasc Imaging. 2011;4(5):574–582.
22. Kim PJ, Mahmoudi M, Ge X, Matsuura Y, Toma I, Metzle S, et al. Direct Evaluation of Myocardial Viability and Stem Cell Engraftment Demonstrates Salvage of the Injured Myocardium. Circ Res. 2015;116(7):e40–e50.
23. McDonald RJ, McDonald JS, Kallmes DF, Jenotof ME, Murray DL, Thielen KR, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275(3), 772–782.
24. Radbruch A, Weberling LD, Kieslich PJ, Eidel S, Burth S, Kickingereder P, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275(3), 783–791.
25. Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, et al. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology. 2015;276(1), 228–232.
26. Messrogli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU & Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6.
27. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006,440(7088), 1217–1221.
28. Pfeffer MA, Pfeffer JM, Steinberg C, & Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72(2), 406–412.
29. Toft KG, Kindberg GM, & Skotland T. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood. J Pharm Biomed Anal. 1997;15(7), 983–988.
30. Toft KG, Hustvedt SO, Grant D, Friisk GA, & Skotland T. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur J Drug Metab Pharmacokinet. 1997;22(1), 65–72.
31. Hustvedt SO, Grant D, Southon TE, Zech K. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol. 1997;38(4 Pt 2), 690–699.
32. Toft KG, Hustvedt SO, Grant D, Martinsen I, Gordon PB, Friisk GA, et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol. 1997;38(4 Pt 2):677–689.
33. Wang C, Gordon PB, Hustvedt SO, Grant D, Sterud AT, Martinsen I, et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol. 1997;38(4 Pt 2), 665–676.
34. Medina DC, Kirkland DM, Tavazoie MF, Springer CS, & Anderson SE. Na+/Ca2+-exchanger-mediated Mn2+-enhanced1H2O MRI in hypoxic, perfused rat myocardium. Contrast Media Mol Imaging. 2007;2(5):248–257.
35. Jablonowski R, Engblom H, Kanski M, Nordlund D, Kou S, van der Pals J, et al. Contrast-Enhanced CMR Overestimates Early Myocardial Infarct Size: Mechanistic Insights Using ECV Measurements on Day 1 and Day 7. JACC Cardiovasc Imaging. 2015;8(12):1379–1389.
36. Dall’Armellina E, Karia N, Lindsay AC, Karamitsos TD, Ferreira V, Robson MD, et al. Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index. Circ Cardiovasc Imaging. 2011;4(3):228–236.
37. Hashmi S, & Al-Salam S. Acute myocardial infarction and myocardial ischemia-reperfusion injury: a comparison. Int J Clin Exp Pathol. 2015;8(8), 8786–8796.
38. Skjold A, Amundsen BH, Wiseth R, Ståylen A, Haraldseth O, Larsson HBW, & Jynge P. Manganese dipyrdoxylyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction. J Magn Reson Imaging. 2007;26(3):720–727.
39. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation. 1994;90(5):2534–2539.
40. Schröder F, Handrock R, Beuckelmann DJ, Hirt S, Hullin R, Priebe L, et al. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation. 1998;98(10), 969–976.